New quinoxalin-1,3,4-oxadiazole derivatives: Synthesis, characterization, in vitro biological evaluations, and molecular modeling studies
| dc.contributor.author | Mirzazadeh, Roghieh | |
| dc.contributor.author | Asgari, Mohammad S. | |
| dc.contributor.author | Barzegari, Ebrahim | |
| dc.contributor.author | Pedrood, Keyvan | |
| dc.contributor.author | Mohammadi-Khanaposhtani, Maryam | |
| dc.contributor.author | Sherafati, Maedeh | |
| dc.contributor.author | Larijani, Bagher | |
| dc.date.accessioned | 2025-10-18T13:23:12Z | |
| dc.date.created | 2021 | |
| dc.date.issued | 2021 | |
| dc.department | Bartın Üniversitesi | |
| dc.description.abstract | A new series of quinoxalin-1,3,4-oxadiazole (10a-l) derivatives was synthesized and evaluated against some metabolic enzymes including human carbonic anhydrase (hCA) isoenzymes I and II (carbonic anhydrases I and II), cholinesterase (acetylcholinesterase and butyrylcholinesterase), and alpha-glucosidase. Obtained data revealed that all the synthesized compounds were more potent as compared with the used standard inhibitors against studied target enzymes. Among the synthesized compounds, 4-fluoro derivative (10f) against hCA I, 4-chloro derivative (10i) against hCA II, 3-fluoro derivative (10e) against acetylcholinesterase and butyrylcholinesterase, and 3-bromo derivative (10k) against alpha-glucosidase were the most potent compounds with inhibitory activity around 1.8- to 7.37-fold better than standard inhibitors. Furthermore, docking studies of these compounds were performed at the active site of their target enzymes. | |
| dc.identifier.doi | 10.1002/ardp.202000471 | |
| dc.identifier.issn | 0365-6233 | |
| dc.identifier.issn | 1521-4184 | |
| dc.identifier.issue | 9 | |
| dc.identifier.orcid | Gulcin, ilhami/0000-0001-5993-1668 | |
| dc.identifier.orcid | Pedrood, Keyvan/0000-0001-6759-9458 | |
| dc.identifier.orcid | Barzegari, Ebrahim/0000-0002-4412-6129 | |
| dc.identifier.orcid | Asgari, Mohammad Sadegh/0009-0000-9977-7044 | |
| dc.identifier.orcid | Taslimi, Parham/0000-0002-3171-0633 | |
| dc.identifier.orcid | Larijani, Bagher/0000-0001-5386-7597 | |
| dc.identifier.orcid | Uc, Eda Mehtap/0000-0002-9259-5704; | |
| dc.identifier.pmid | 33999440 | |
| dc.identifier.scopus | 2-s2.0-85105800867 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.uri | https://doi.org/10.1002/ardp.202000471 | |
| dc.identifier.uri | https://hdl.handle.net/11772/22740 | |
| dc.identifier.volume | 354 | |
| dc.identifier.wos | WOS:000651131800001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Wiley-V C H Verlag Gmbh | |
| dc.relation.ispartof | Archiv Der Pharmazie | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | WoS_20251016 | |
| dc.subject | 1,3,4-Oxadiazole | |
| dc.subject | Carbonic Anhydrase | |
| dc.subject | Cholinesterase | |
| dc.subject | Quinoxalin | |
| dc.subject | Alpha-Glucosidase | |
| dc.title | New quinoxalin-1,3,4-oxadiazole derivatives: Synthesis, characterization, in vitro biological evaluations, and molecular modeling studies | |
| dc.type | Article | |
| dspace.entity.type | Publication |










